Actively Recruiting
Phase II Randomized Double-Masked Crossover Study of rhPRG4 Eye Drops Compared to Placebo for Treating Ocular Graft-Versus-Host Disease
Led by Lubris Bio Pty Ltd · Updated on 2026-10-26
15
Participants Needed
3
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of rhPRG4 450 gml recombinant human proteoglycan 4 compared to a placebo vehicle in treating moderate to severe ocular Graft-Versus-Host Disease oGVHD related dry eye disease. This Phase II, randomized, double-masked crossover study involves adults aged 18 to 75 years who have had oGVHD diagnosed for at least three months. The study aims to assess changes in corneal staining and dry eye symptoms using specific scales over 28 days of treatment. Participants will receive both treatments, rhPRG4 and a placebo vehicle, in random order. Each treatment is administered for 28 days, separated by a 14-day washout period without treatment. This crossover design allows comparison within the same participant. Treatments are self-administered eye drops during the treatment periods. Throughout the 84-day study, participants will attend scheduled clinic visits for evaluations including eye examinations, symptom questionnaires, visual acuity tests, and safety monitoring such as intraocular pressure measurement. Researchers will assess both the efficacy and safety of rhPRG4, focusing on corneal staining and symptom scores as primary outcomes. Participants are expected to adhere to the medication regimen and attend all visits during the study duration.
CONDITIONS
Brief Title
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Research Team
E
Edward CEO
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here